Dormizol Mechanism of Action





Phil Pharmawealth
Full Prescribing Info
Pharmacology: Benzodiazepines appear to intensify the physiologic inhibitory mechanisms mediated by gamma-aminobutyric acid (GABA), the most common inhibitory neurotransmitter in the brain. The effects of Midazolam on the CNS are dependent on the dose administered, the route of administration and the presence or absence of other premedications.
Mechanism of Action: Midazolam is a drug acting on psychic function, behavior, or experience which alters the mental state by affecting the neurophysiological and biochemical activity of the functional units of the CNS, or in the pharmacological sense, as narcotics.
Pharmacokinetics: The absorption of Midazolam is rapid. The peak plasma concentration is achieved within 20 to 60 minutes of administration depending on the route. The mean absolute bioavailability of Midazolam following I.M. administration is greater than 90%. In a pharmacokinetics study in children, the bioavailability of a dose of 150mcg per kg body weight was 100% and 87% after administration by the I.V. and I.M. routes respectively. Midazolam is lipophilic at physiological pH. It crosses the placenta and is distributed into breast milk. Midazolam is about 96% bound to plasma proteins. Its elimination half-life of Midazolam is about 2 hours although half lives longer than 7 hours been reported in some patients. The half-life of Midazolam is prolonged in neonates, in the elderly, and in patients with liver disorders.
The drug is rapidly metabolized to I-hydroxymethylmidazolam which is conjugated with subsequent excretion in the urine, mainly as glucuronide conjugates. The half-life of elimination of the active metabolite is similar to Midazolam.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in